Pfizer Inc. stock at EUR 25.21, up 18.0 percent year to date

Published on 10/09/2026 at 20:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer stock was EUR 25.21 on October 9, 2026, versus EUR 24.79. US value was USD 160.8 billion and the year-to-date gain was 18.0 percent.

Key points in brief

Pfizer Inc. stock was EUR 25.21 at Lang & Schwarz on October 9, 2026 at 8:00 p.m. CEST, plus 1.69 percent versus EUR 24.79.
The NYSE quote was USD 28.21 at 2:04 p.m. ET, while the 2026 year-to-date gain was 18.0 percent.
Cantor Fitzgerald raised its target from USD 27.00 to USD 28.00 and kept a Neutral rating on October 8, 2026.
Pfizer's next reported results are scheduled for November 3, 2026.

Pop-Art-Comic mit Wissenschaftler und großer Kapsel, Symbolbild für Pfizer Inc — Farbenfrohe Pop-Art-Comicszene mit Wissenschaftler und Kapsel greift die Branche Pfizer Inc., ISIN US7170811035, humorvoll auf, Illustration mit AI erstellt.

Pfizer Inc. stock (ISIN US7170811035) was trading at EUR 25.21 at Lang & Schwarz on October 9, 2026 at 8:00 p.m. CEST, up 1.69 percent versus the prior close of EUR 24.79. The same-day NYSE quote was USD 28.21 at 2:04 p.m. ET, giving investors two clearly separated currency views of the market.

Intraday pricing stays active

Pfizer's bid was EUR 25.20 and its ask was EUR 25.22 at Lang & Schwarz on October 9, 2026. On the NYSE, the stock's daily move was plus 1.40 percent at the quoted time, while trading volume reached 13,358,836 shares against an average of 36,178,415 shares.

Year to date and range

The NYSE price sat between a 52-week low of USD 23.62 and a high of USD 29.21 on October 9, 2026. The year-to-date performance was 18.0 percent, placing the stock closer to its annual high than its low in the home-market currency.

For valuation, Pfizer's market capitalization was USD 160.8 billion and its trailing P/E ratio was 37.3 on October 9, 2026. The trailing dividend yield was 6.0 percent, so income remains a visible part of the stock's market profile even as the valuation multiple stands well above Bristol-Myers Squibb's.

Analyst target stays near price

MarketBeat reported on October 8, 2026 that Cantor Fitzgerald raised its Pfizer target from USD 27.00 to USD 28.00 while keeping a Neutral rating. The same report put the 21-analyst consensus at Hold with an average target of USD 28.61, making the target discussion a modest valuation reference rather than a decisive change in the market profile.

Comparison with peers

Pfizer Inc.: plus 1.69 percent, P/E 37.3, market capitalization USD 160.8 billion

Merck & Co., Inc. (NYSE, USD): plus 2.73 percent, P/E 117.0, market capitalization USD 361.2 billion

Bristol-Myers Squibb Company (NYSE, USD): plus 0.02 percent, P/E 13.1, market capitalization USD 121.7 billion

Next reporting date

Pfizer scheduled its third-quarter 2026 results webcast for November 3, 2026, at 10:00 a.m. EST. The date gives the market a defined calendar point for the next fundamental update.

Price and market context

Pfizer's euro quote was EUR 25.21 at Lang & Schwarz on October 9, 2026 at 8:00 p.m. CEST, plus 1.69 percent versus the Lang & Schwarz prior close of EUR 24.79. The NYSE quote was USD 28.21 at 2:04 p.m. ET on the same date, and the 52-week range was USD 23.62 to USD 29.21.

The further course of trading is shown by the continuously updated real-time quote of Pfizer Inc. stock.